| Texto completo | |
| Autor(es): |
Keppeke, Gerson Dierley
[1]
;
Calise, S. John
[2]
;
Chan, Edward K. L.
[2]
;
Andrade, Luis Eduardo C.
[3, 1]
Número total de Autores: 4
|
| Afiliação do(s) autor(es): | [1] Univ Fed Sao Paulo, Escola Paulista Med, Div Rheumatol, Rua Botucatu 740, BR-04023062 Sao Paulo, SP - Brazil
[2] Univ Florida, Dept Oral Biol, Gainesville, FL 32610 - USA
[3] Fleury Med & Hlth Labs, Div Immunol, BR-04102050 Sao Paulo, SP - Brazil
Número total de Afiliações: 3
|
| Tipo de documento: | Artigo Científico |
| Fonte: | WORLD JOURNAL OF GASTROENTEROLOGY; v. 22, n. 6, p. 1966-1974, FEB 14 2016. |
| Citações Web of Science: | 11 |
| Resumo | |
Chronic inflammation associated with hepatitis C virus (HCV) infection can lead to disabling liver diseases with progression to liver cirrhosis and hepatocellular carcinoma. Despite the recent availability of more effective and less toxic therapeutic options, in most parts of the world the standard treatment consists of a weekly injection of pegylated interferon a (IFN-alpha) together with a daily dose of ribavirin. HCV patients frequently present circulating non-organ-specific autoantibodies demonstrating a variety of staining patterns in the indirect immunofluorescence assay for antinuclear antibodies (ANA). Between 20% to 40% of HCV patients treated with IFN-a and ribavirin develop autoantibodies showing a peculiar ANA pattern characterized as rods and rings (RR) structures. The aim of this article is to review the recent reports regarding RR structures and anti-rods/rings (anti-RR) autoantibody production by HCV patients after IFN-alpha/ribavirin treatment. Anti-RR autoantibodies first appear around the sixth month of treatment and reach a plateau around the twelfth month. After treatment completion, anti-RR titers decrease/disappear in half the patients and remain steady in the other half. Some studies have observed a higher frequency of anti-RR antibodies in relapsers, i. e., patients in which circulating virus reappears after initially successful therapy. The main target of anti-RR autoantibodies in HCV patients is inosine-5 ` n-monophosphate dehydrogenase 2 (IMPDH2), the rate-limiting enzyme involved in the guanosine triphosphate biosynthesis pathway. Ribavirin (AU) | |
| Processo FAPESP: | 11/12448-0 - Anticorpos anti-"Rods & Rings", HCV e ribavirina/interferon: um Modelo Humano de Geração de Autoanticorpos |
| Beneficiário: | Gerson Dierley Keppeke |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |